SCHEMBL458049

SCHEMBL458049

C/C=C\CC(N)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL866068 1.00
SCHEMBL8186027 1.00
SCHEMBL8186028 1.00
SCHEMBL13406449 1.00
SCHEMBL14388431 1.00
SCHEMBL458050 1.00
SCHEMBL15703578 1.00
Hydrochloric Acid SCHEMBL713389 0.98 GRIK1 (0.66)
Hydrochloric Acid SCHEMBL712566 0.98 GRIK1 (0.66)
Hydrochloric Acid SCHEMBL2523802 0.98 GRIK1 (0.66)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4071477-B1 COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENT QIAGEN SCIENCES LLC (US) 2026-01-21 EP disclosed
US-20240384267-A1 COMPOSITIONS AND METHODS FOR MULTIPLEX DECODING OF QUADRUPLET CODONS THE BROAD INSTITUTE, INC. 2024-11-21 US disclosed
US-20240361314-A1 COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENT QIAGEN SCIENCES LLC (US) 2024-10-31 US disclosed
US-20240294586-A1 TENASCIN-C AUTOANTIGENIC EPITOPES IN RHEUMATOID ARTHRITIS BENAROYA RES INSTITUTE AT VIRGINIA MASON (US) 2024-09-05 US disclosed
US-12066436-B2 Compositions and methods for diagnosing Lyme disease and for predicting Lyme disease spirochete elimination after treatment QIAGEN SCIENCES LLC (US) 2024-08-20 US disclosed
US-20240027450-A1 COMPOSITIONS AND METHODS FOR DIAGNOSING SARS-COV-2 (COVID-19) AND FOR MONITORING SARS-COV-2-SPECIFIC IMMUNOLOGICAL MEMORY QIAGEN SCIENCES LLC 2024-01-25 US disclosed
EP-4256334-A1 COMPOSITIONS AND METHODS FOR DIAGNOSING SARS-COV-2 (COVID-19) AND FOR MONITORING SARS-COV-2-SPECIFIC IMMUNOLOGICAL MEMORY Qiagen Sciences LLC (US) 2023-10-11 EP disclosed
WO-2023069816-A2 COMPOSITIONS AND METHODS FOR MULTIPLEX DECODING OF QUADRUPLET CODONS THE BROAD INSTITUTE, INC. (US) 2023-04-27 WO disclosed
EP-3353551-B1 COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENT QIAGEN SCIENCES LLC (US) 2022-11-02 EP disclosed
EP-4071477-A1 COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENT QIAGEN Sciences, LLC (US) 2022-10-12 EP disclosed
US-20080026422-A1 Adding an desired amino acid analog to a medium containing a host cell with a vector coding for aminoacyl-tRNA synthetase and a vector coding for the polypeptide of interest; and growing the cell to produce the modified polypeptide CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2008-01-31 US disclosed
WO-2008005531-A2 C-MET RECEPTOR REGULATION BY ANGIOTENSIN IV (AT4) RECEPTOR LIGANDS WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) 2008-01-10 WO disclosed
US-20080008701-A1 C-MET RECEPTOR REGULATION BY ANGIOTENSIN IV (AT4) RECEPTOR LIGANDS WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) 2008-01-10 US disclosed
WO-2007130453-A2 NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES ALLOZYNE, INC. (US) 2007-11-15 WO disclosed
WO-2007103307-A2 SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2007-09-13 WO disclosed
US-7198915-B2 Preparing modified/artificial polypeptides; mimetics CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2007-04-03 US disclosed
US-7198915-B2 Preparing modified/artificial polypeptides; mimetics CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2007-04-03 US disclosed
US-20040058415-A1 Preparing modified/artificial polypeptides; mimetics CALIFORNIA INSTITUTE OF TECHNOLOGY 2004-03-25 US disclosed
US-6586207-B2 Host cell is a methionine auxotroph; methionine-tRNA synthetase overexpressed in presence of analogues and absence of methionine; protein is modified dihydrofolate reductase CALIFORNIA INSTITUTE OF TECHNOLOGY 2003-07-01 US disclosed
US-20020042097-A1 Host cell is a methionine auxotroph; methionine-tRNA synthetase overexpressed in presence of analogues and absence of methionine; protein is modified dihydrofolate reductase CALIFORNIA INSTITUTE OF TECHNOLOGY 2002-04-11 US disclosed